# **REHABILITY for TeleRehabilitation**

Lucia Pannese, CEO Imaginary srl



# The Challenge

Worldwide healthcare systems are seriously challenged

Direct costs of chronic patients

Stroke: €20 Billion in 2015; ~€30 Billion in 2035 Nr. specialists

VS

Nr chronic patients


Long waiting lists
&
Short therapies
create new
occurrences
+
Loss of
productivity



Eurostat health office trends: **increasing number of home caring professionals NOT SCALABLE!** 



#### **The Solution**



**Video:** <a href="https://www.youtube.com/watch?v=tmRJj8MjezU&t=8s">https://www.youtube.com/watch?v=tmRJj8MjezU&t=8s</a>





Scalable, Game-based Tele-rehabilitation Software

Own IP

CF medical device class I

4 types of patients:

Post Stroke, MS, Parkinson's, Spinal

Cord Injury

22 scientific papers published

6 international awards

#### **The Solution**





Best Presentation Award at Healthtech Invest Europe, Helsinki, March 2017




Awarded at the Pitch Competition Frontiers Conference 2017



1<sup>st</sup> prize in AboutPharma Digital Awards (Oct 2015) for the category "reorganization of the NHS" and is in the top 3 nominations in the category of "Tech for Patients".



# - Roadmap



Grants €225.000

Grants €345.000

Grants €235.000

CE Mark

Fund Raising Expansion



# **Market Opportunity**

#### TAM in Europe:

14 million patients with neurodegenerative diseases, expected to rise by 25% till 2030 (CAGR 2.2%)

+ 9.53 million stroke survivors (in 2017), est. to increase by 27% between 2017 and 2047

B2B Solution for clinics and rehab centres, NHS,...

SAM in Europe:

7.500.000 patients approximately

SOM:
0.02% (2023)
0.06% (2024)
0.15% (2025)

https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.029606#:~:text=these%20missing%20values.-,Results,million%20DALYs%20lost%20(Table).



<sup>\*</sup>partial geographical coverage, not all neurology patients can be treated with REHABILITY

# **Main Competitors – Competitive Advantage**

- Game-based: mostly with weak scientific background, not co-designed with patients,
   often too generic in the medical objective
- Tele-conference with therapist: is not scalable
- Solutions with wearable devices: are not easy to use, not cheap
- Immersive VR (glasses): too high risk for patients, no scientific validation
- Video based (e.g. app): not interactive, no data collection, no personalised therapy



## **Business Model**

B2B Solution with yearly licenses

Revenue Streams:

Licenses:


Clinic license (unlimited) Home license (single patient) Services:

installation training maintenance Hardware:

Home kits (set top box + RGBD camera)



#### **Traction**



#### Current Customers include :

Pfizer & Novartis
It Association for MS
Osakidetza, Spain
Istituto Neurologico Carlo Besta
A.O.U. San Luigi Gonzaga



# **Management Team**






Lucia Pannese, partner, CEO







Mauro Santalmasi, partner, customer care





Vito Nitti, partner, CTO




# What we are looking for

Raising now: €2M

Team expansion

International expansion





International network of distributors



#### **Contact**





## Lucia Pannese, CEO Imaginary



lucia.pannese@i-maginary.it



www.i-maginary.it



imaginary.italy



imaginarysrl



imaginary\_italy

piazza Caiazzo, 3 20124 Milano PH. +39 02 89458.576 MOB +39 338 8785839

